Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted <scp>CAR</scp> in peripheral blood
Won‐Ho Lee, Charlotte Graham, Hadley R. Wiggin, Hannah K. Nolan, Kiana Graham, Felix Korell, Mark B. Leick, Alexis Barselau, Estelle Emmanuel‐Alejandro, Michael Trailor, Juliane M. Gildea, Frederic I. Preffer, Matthew J. Frigault, Marcela V. Maus, Kathleen Gallagher
Abstract
Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there are limited options for reliable BCMA CAR T detection assays for physicians and researchers looking to explore it as a biomarker for clinical outcome. Given the known association of CAR T cell expansion kinetics with toxicity and response, being able to quantify BCMA CAR T cells routinely and accurately in the blood of patients can serve as a valuable asset. Here, we optimized an accurate and sensitive flow cytometry test using a PE-conjugated soluble BCMA protein, with a lower limit of quantitation of 0.19% of CD3+ T cells, suitable for use as a routine assay for monitoring the frequency of BCMA CAR T cells in the blood of patients receiving either ciltacabtagene autoleucel or idecabtagene vicleucel.